| 8.5 0.03 (0.35%) | 12-08 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.22  |
1-year : | 11.93 |
| Resists | First : | 8.75 |
Second : | 10.22 |
| Pivot price | 6.99 |
|||
| Supports | First : | 6.78 |
Second : | 5.57 |
| MAs | MA(5) : | 8.13 |
MA(20) : | 6.79 |
| MA(100) : | 7.4 |
MA(250) : | 7.34 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 94.1 |
D(3) : | 94.7 |
| RSI | RSI(14): 72.5 |
|||
| 52-week | High : | 11.14 | Low : | 3.46 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ MRNS ] has closed below upper band by 7.8%. Bollinger Bands are 69.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 8.76 - 8.78 | 8.78 - 8.81 |
| Low: | 8.2 - 8.23 | 8.23 - 8.27 |
| Close: | 8.45 - 8.49 | 8.49 - 8.54 |
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, tuberous sclerosis complex, depressive disorders, and Lennox-Gestaut Syndrome. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.
Thu, 07 Dec 2023
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
Mon, 20 Nov 2023
Marinus Pharmaceuticals Announces Seven Presentations at AES 2023, New Publication in Epilepsia and Results ... - Business Wire
Tue, 14 Nov 2023
Marinus Pharmaceuticals to Present at the 6th Annual Evercore ISI HealthCONx Conference - Business Wire
Wed, 08 Nov 2023
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q3 2023 Earnings Call Transcript - Yahoo Finance
Tue, 07 Nov 2023
Marinus Pharmaceuticals: Q3 Earnings Snapshot - Quartz
Tue, 07 Nov 2023
Marinus Pharmaceuticals Inc (MRNS) Reports Q3 2023 Financial Results - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 55 (M) |
| Shares Float | 43 (M) |
| Held by Insiders | 0.7 (%) |
| Held by Institutions | 86.4 (%) |
| Shares Short | 4,550 (K) |
| Shares Short P.Month | 3,850 (K) |
| EPS | -2.78 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1 |
| Profit Margin | 0 % |
| Operating Margin | -431.3 % |
| Return on Assets (ttm) | -40.6 % |
| Return on Equity (ttm) | -196.2 % |
| Qtrly Rev. Growth | 213.6 % |
| Gross Profit (p.s.) | -1.03 |
| Sales Per Share | 0.56 |
| EBITDA (p.s.) | -2.19 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -113 (M) |
| Levered Free Cash Flow | -75 (M) |
| PE Ratio | -3.06 |
| PEG Ratio | -0.2 |
| Price to Book value | 8.5 |
| Price to Sales | 14.98 |
| Price to Cash Flow | -4.11 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|